指南与共识前列腺癌

前列腺特异性抗原检测作为风险适配性前列腺癌早期筛查策略:欧洲泌尿外科学会2021年立场与推荐

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
指南 / 共识 · Eur Urol · 2021-08-15

欧洲泌尿外科学会(EAU)基于文献综述与专家意见,提出针对充分知情男性的风险适配性前列腺癌早期检测策略,结合PSA检测、风险计算器与多参数磁共振成像,以区分显著与非显著前列腺癌。该策略旨在减少过度诊断与过度治疗,同时促进显著癌的早期诊断与治疗,并可能降低晚期诊断率与前列腺癌特异性死亡率。

要点

  • EAU推荐采用基于PSA检测、风险计算器与mpMRI的风险适配性早期检测策略。
  • 该策略可区分显著与非显著前列腺癌,减少过度诊断与过度治疗。
  • 需对泌尿科医生、全科医生、放射科医生、政策制定者及健康男性开展教育。

核心结论

  • 风险适配性早期检测策略将逆转当前不利趋势并最终挽救生命。

研究设计与样本

  • EAU专家意见,结合相关文献综述(包括2021年EAU前列腺癌指南更新)与专家知识。

主要发现

  • 2012年反对PSA检测的建议增加了晚期诊断与前列腺癌特异性死亡率。
  • 风险适配性策略基于PSA检测、风险计算器与多参数磁共振成像,可区分显著与非显著前列腺癌。
  • 该策略 largely 避免对终生 unlikely 出现疾病相关症状的男性过度诊断/过度治疗。
  • 该策略促进显著癌男性的早期诊断以接受主动治疗,并减少晚期诊断。

关键数值与推荐

  • EAU推荐对充分知情的男性采用基于PSA检测、风险计算器与多参数磁共振成像的风险适配性早期检测策略。
  • 需欧洲委员会认可并调整2022年计划中的欧洲理事会筛查建议,并要求各国纳入国家癌症计划。

临床怎么用

  • 对充分知情且面临显著前列腺癌风险的男性提供PSA检测。
  • 使用风险计算器与多参数磁共振成像区分显著与非显著前列腺癌,避免不必要的MRI或活检。
  • 向患者提供EAU患者信息 leaflet 与算法以辅助早期诊断决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recommendations against prostate-specific antigen (PSA) testing in 2012 have increased advanced-stage diagnosis and prostate cancer-specific mortality rates. OBJECTIVE: To present the position of the European Association of Urology (EAU) in 2021 and provide recommendations for the use of PSA testing as part of a risk-adapted strategy for the early detection of prostate cancer. EVIDENCE ACQUISITION: The authors combined their review of relevant literature, including the EAU prostate cancer guidelines 2021 update, with their own knowledge to provide an expert opinion, representing the EAU's position in 2021. EVIDENCE SYNTHESIS: The EAU has developed a risk-adapted early prostate cancer detection strategy for well-informed men based on PSA testing, risk calculators, and multiparametric magnetic resonance imaging, which can differentiate significant from insignificant prostate cancer. This approach largely avoids the overdiagnosis/overtreatment of men unlikely to experience disease-related symptoms during their lifetime and facilitates an early diagnosis of men with significant cancer to receive active treatment. It also reduces advanced-stage diagnosis, thereby potentially reducing prostate cancer-specific mortality and improving quality of life. Education is required among urologists, general practitioners, radiologists, policy makers, and healthy men, including endorsement by the European Commission to adapt the European Council's screening recommendations in its 2022 plan and requests to individual countries for its incorporation into national cancer plans. CONCLUSIONS: This risk-adapted approach for the early detection of prostate cancer will reverse current unfavourable trends and ultimately save lives. PATIENT SUMMARY: The European Association of Urology has developed a patient information leaflet and algorithm for the early diagnosis of prostate cancer. It can identify men who do not need magnetic resonance imaging or a biopsy and those who would not show any symptoms versus those with more aggressive disease who require further tests/treatment. We need to raise awareness of this algorithm to ensure that all well-informed men at risk of significant prostate cancer are offered a prostate-specific antigen test.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021. PMID: 34407909. doi:10.1016/j.eururo.2021.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。